Avalo Therapeutics (AVTX) Total Current Liabilities (2014 - 2026)
Avalo Therapeutics (AVTX) posted Total Current Liabilities of $11.6 million for Q1 2026, down 10.36% on a QoQ basis from $12.9 million in Q4 2025, and up 106.57% year-over-year from $5.6 million in Q1 2025.
Avalo Therapeutics (AVTX) Total Current Liabilities (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $11.6 million for Q1 2026.
- Quarterly Total Current Liabilities rose 106.57% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 106.57% YoY) and the FY2025 annual result came in at $12.9 million, up 85.92% from the prior year.
- Total Current Liabilities was $11.6 million for Q1 2026 at Avalo Therapeutics, down from $12.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $215.7 million in Q1 2024 and bottomed at $4.6 million in Q4 2023.
- A 5-year average of $32.8 million and a median of $15.4 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 910.39% — and 2025, when it slumped 97.4%.
- Avalo Therapeutics' Total Current Liabilities stood at $22.1 million in 2022, then plunged by 79.12% to $4.6 million in 2023, then jumped by 50.71% to $7.0 million in 2024, then surged by 85.92% to $12.9 million in 2025, then slipped by 10.36% to $11.6 million in 2026.
- Business Quant data shows AVTX's Total Current Liabilities at $11.6 million in Q1 2026, $12.9 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 11.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.60 Mn |
| Dec 31, 2025 | 12.94 Mn |
| Sep 30, 2025 | 7.97 Mn |
| Jun 30, 2025 | 9.26 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 6.96 Mn |
| Sep 30, 2024 | 60.67 Mn |
| Jun 30, 2024 | 96.40 Mn |
| Mar 31, 2024 | 215.70 Mn |
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 6.01 Mn |
| Jun 30, 2023 | 22.45 Mn |
| Mar 31, 2023 | 23.25 Mn |
| Dec 31, 2022 | 22.11 Mn |
| Sep 30, 2022 | 18.15 Mn |
| Jun 30, 2022 | 15.40 Mn |
| Mar 31, 2022 | 17.89 Mn |
| Dec 31, 2021 | 19.89 Mn |
| Sep 30, 2021 | 19.04 Mn |
| Jun 30, 2021 | 21.67 Mn |